Literature DB >> 26781260

Management of osteogenesis imperfecta type I in pregnancy; a review of literature applied to clinical practice.

Mauro Cozzolino1, Federica Perelli2, Luana Maggio2, Maria Elisabetta Coccia2, Michela Quaranta3, Salvatore Gizzo4, Federico Mecacci2.   

Abstract

PURPOSE: Osteogenesis imperfecta (OI) is a rare heritable heterogenous disorder characterized by bone fragility and susceptibility to fractures with a wide spectrum of clinical expression due to defects in collagen type I biosynthesis. The purpose of the review is to highlight the practical norms in pregnancies with osteogenesis imperfecta.
METHODS: We carried out a literature review in MEDLINE on OI during pregnancy, focusing on diagnosis, therapy and delivery. We reviewed 28 articles (case reports, original articles and reviews).
RESULTS: Pregnant women affected by type I OI should be closely monitored to assess fetal well-being and detect pregnancy-related complications associated with an increased risk for osteoporosis, restrictive pulmonary disease, cephalopelvic disproportion and other problems related to connective tissue disorders. Mode of delivery remains controversial and should be determined on an individual basis.
CONCLUSION: In conclusion, women affected by type I OI represent a subset of patients whose pregnancies should be considered high risk and warrant a multidisciplinary approach in a referral center.

Entities:  

Keywords:  Anesthesiologic technique; Biphosphonates; Osteogeneis imperfecta; Pregnancy

Mesh:

Substances:

Year:  2016        PMID: 26781260     DOI: 10.1007/s00404-016-4012-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  9 in total

1.  Mutational analysis uncovers monogenic bone disorders in women with pregnancy-associated osteoporosis: three novel mutations in LRP5, COL1A1, and COL1A2.

Authors:  S Butscheidt; A Delsmann; T Rolvien; F Barvencik; M Al-Bughaili; S Mundlos; T Schinke; M Amling; U Kornak; R Oheim
Journal:  Osteoporos Int       Date:  2018-03-29       Impact factor: 4.507

2.  Pamidronate Administration During Pregnancy and Lactation Induces Temporal Preservation of Maternal Bone Mass in a Mouse Model of Osteogenesis Imperfecta.

Authors:  Diana Olvera; Rachel Stolzenfeld; Emily Fisher; Bonnie Nolan; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2019-10-09       Impact factor: 6.741

3.  Pregnancy outcomes in women with osteogenesis imperfecta: a retrospective cohort study.

Authors:  J Ruiter-Ligeti; N Czuzoj-Shulman; A R Spence; T Tulandi; H A Abenhaim
Journal:  J Perinatol       Date:  2016-07-21       Impact factor: 2.521

4.  Pregnancy in women with osteogenesis imperfecta: pregnancy characteristics, maternal, and neonatal outcomes.

Authors:  Rashmi Rao; David Cuthbertson; Sandesh C S Nagamani; Vernon Reid Sutton; Brendan H Lee; Jeffrey Krischer; Deborah Krakow
Journal:  Am J Obstet Gynecol MFM       Date:  2021-03-26

5.  Anesthetic Management in a Gravida with Type IV Osteogenesis Imperfecta.

Authors:  Elizabeth Vue; Juan Davila; Tracey Straker
Journal:  Case Rep Med       Date:  2016-06-28

6.  Abnormal pelvic morphology and high cervical length are responsible for high-risk pregnancies in women displaying achondroplasia.

Authors:  Alexandre J Vivanti; Anne-Gael Cordier; Geneviève Baujat; Alexandra Benachi
Journal:  Orphanet J Rare Dis       Date:  2016-12-05       Impact factor: 4.123

7.  Novel mutation of FKBP10 in a pediatric patient with osteogenesis imperfecta type XI identified by clinical exome sequencing.

Authors:  Harvy Mauricio Velasco; Jessica L Morales
Journal:  Appl Clin Genet       Date:  2017-11-07

Review 8.  Reproductive options for families at risk of Osteogenesis Imperfecta: a review.

Authors:  Lidiia Zhytnik; Kadri Simm; Andres Salumets; Maire Peters; Aare Märtson; Katre Maasalu
Journal:  Orphanet J Rare Dis       Date:  2020-05-27       Impact factor: 4.123

9.  Osteogenesis imperfecta and pregnancy: a case report.

Authors:  Felix Chamunyonga; Kudzaishe Lloyd Masendeke; Bismark Mateveke
Journal:  J Med Case Rep       Date:  2019-12-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.